<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0001-6002</journal-id>
<journal-title><![CDATA[Acta Médica Costarricense]]></journal-title>
<abbrev-journal-title><![CDATA[Acta méd. costarric]]></abbrev-journal-title>
<issn>0001-6002</issn>
<publisher>
<publisher-name><![CDATA[Colegio de Médicos y Cirujanos de Costa Rica]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0001-60022017000400164</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Sangrado espontáneo masivo en adulto conocido sano]]></article-title>
<article-title xml:lang="en"><![CDATA[Massive spontaneous bleeding]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alfaro-Murillo]]></surname>
<given-names><![CDATA[Alberto J.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Dobles-Ramírez]]></surname>
<given-names><![CDATA[Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Salas-Segura]]></surname>
<given-names><![CDATA[Donato A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Costa Rica Hospital &#8220;Dr. Rafael Ángel Calderón Guardia Unidad Cuidado Intensivo]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Costa Rica</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2017</year>
</pub-date>
<volume>59</volume>
<numero>4</numero>
<fpage>164</fpage>
<lpage>166</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_arttext&amp;pid=S0001-60022017000400164&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_abstract&amp;pid=S0001-60022017000400164&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_pdf&amp;pid=S0001-60022017000400164&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen Se reporta el caso de un paciente que presentó de manera espontánea diátesis hemorrágica, sin tener causa alguna aparente que lo justificase. Tal diátesis hemorrágica forja un amplio apartado de posibilidades diagnósticas en cuanto a trastornos de la coagulación del adulto se refiere, en el contexto de un paciente conocido sano que nunca ha presentado episodios de sangrado mayor y debuta con hemorragias de forma masiva. Entre las muchas posibilidades diagnósticas se encuentra una poco conocida: la hemofilia adquirida. La hemofilia adquirida es un trastorno infrecuente de la hemostasia, caracterizado por la presencia de inhibidores adquiridos de los factores de la coagulación, en el plasma del paciente enfermo. Los inhibidores adquiridos son anticuerpos que a su vez podrían ser de tipo aloanticuerpos o autoanticuerpos. Los aloanticuerpos se desarrollan en pacientes deficitarios per se de factores de la coagulación, en respuesta a la terapia de sustitución de factores, lo que complica su tratamiento. Por su parte, los autoanticuerpos se desarrollan en sujetos sin defectos previos; son anticuerpos específicos contra un factor de la coagulación, afectando o no su función, alterando una o varias etapas de las vías de la coagulación. El caso que aquí se presenta es de un paciente masculino de 58 años, quien se presentó con sangrado espontáneo masivo y a quien se diagnosticó hemofilia adquirida por la presencia de autoanticuerpo específico del factor VIII.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract A patient that presented with spontaneous hemorrhagic diathesis, with no apparent cause is presented. Hemorrhagic diathesis presents a wide range of diagnosis possibilities as of coagulation disorders are referred, in the context of a healthy patient with no previous major bleeding episodes and that debuts with massive hemorrhages. Acquired hemophilia, a little known disease, is one that must be considered. Acquired hemophilia is an uncommon hemostasis disorder characterized by the presence of acquired inhibitors of coagulation factors in the plasma of the sick patient. These acquired inhibitors, are antibodies that could be alloantibodies or autoantibodies. Alloantibodies are developed in patients who have coagulation factor deficiency, in response to factor replacement therapy, thus complicating treatment. On the other hand, autoantibodies are developed in people without previous defects and are specific against a factor of coagulation, affecting or not their function, obstructing one or several stages of the coagulation pathways. We report a case of acquired hemophilia due to an autoantibody against factor VIII in a 58 years old male patient with spontaneous massive bleeding.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[hemorragia]]></kwd>
<kwd lng="es"><![CDATA[factor VIII]]></kwd>
<kwd lng="es"><![CDATA[plasmaféresis]]></kwd>
<kwd lng="es"><![CDATA[sangrado masivo]]></kwd>
<kwd lng="es"><![CDATA[hemofilia adquirida]]></kwd>
<kwd lng="en"><![CDATA[Hemorrhage]]></kwd>
<kwd lng="en"><![CDATA[Factor VIII]]></kwd>
<kwd lng="en"><![CDATA[plasmapheresis]]></kwd>
<kwd lng="en"><![CDATA[spontaneous bleeding]]></kwd>
<kwd lng="en"><![CDATA[acquired hemophilia]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Remotti]]></surname>
<given-names><![CDATA[Lucía]]></given-names>
</name>
<name>
<surname><![CDATA[Haydée]]></surname>
<given-names><![CDATA[Silvia]]></given-names>
</name>
<name>
<surname><![CDATA[Feancisco]]></surname>
<given-names><![CDATA[Marcelo]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inhibidores adquiridos de la coagulación: enfoque diagnóstico y casos especiales]]></article-title>
<source><![CDATA[ABCL]]></source>
<year>2016</year>
<volume>50</volume>
<page-range>291-301</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Franchini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Castaman]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Coppola]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Santoro]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Zanon]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Di Minno]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[AICE Working Group. Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management]]></article-title>
<source><![CDATA[Blood Transfus]]></source>
<year>2015</year>
<volume>13</volume>
<page-range>498-513</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Franchini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lippi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Favaloro]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acquired inhibitors of coagulation factors: part II]]></article-title>
<source><![CDATA[Semin Thromb Hemost]]></source>
<year>2012</year>
<volume>38</volume>
<page-range>447-53</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brandt]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Triplett]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Alving]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Scharrer]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Criteria for the diagnosis of lupus anticoagulants: an update]]></article-title>
<source><![CDATA[Thromb Haemost]]></source>
<year>1995</year>
<volume>74</volume>
<page-range>1185-90</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pierangeli]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[de Groot]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[Dlott]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Favaloro]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[EN]]></given-names>
</name>
<name>
<surname><![CDATA[Lakos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Criteria&#8217; aPL tests: Report of a Task Force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010]]></article-title>
<source><![CDATA[Lupus]]></source>
<year>2011</year>
<volume>20</volume>
<page-range>182-90</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blanco]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inhibidores adquiridos de la coagulación y otros desórdenes inmunológicos]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Blanco]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kordich]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bermejo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Forastiero]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lauricella]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Pieroni]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Quintana]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Scazziota]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Fundamentos para el manejo práctico en el laboratorio de hemostasia]]></source>
<year>2013</year>
<edition>2</edition>
<page-range>517-83</page-range><publisher-loc><![CDATA[La Plata ]]></publisher-loc>
<publisher-name><![CDATA[Federación Bioquímica de la Provincia de Buenos Aires]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kershaw]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Favaloro]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Laboratory identification of factor inhibitors: an update]]></article-title>
<source><![CDATA[Pathology]]></source>
<year>2012</year>
<volume>44</volume>
<page-range>293-302</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Favaloro]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Verbruggen]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Laboratory testing for factor inhibitors]]></article-title>
<source><![CDATA[Haemophilia]]></source>
<year>2014</year>
<volume>20</volume>
<numero>^s4</numero>
<issue>^s4</issue>
<supplement>4</supplement>
<page-range>94-8</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Collins]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Chalmers]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Hart]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Jennings]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Liesner]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rangarajan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO]]></article-title>
<source><![CDATA[Br J Haematol]]></source>
<year>2013</year>
<volume>162</volume>
<page-range>758-73</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
